Last reviewed · How we verify

NephroNet, Inc. — Portfolio Competitive Intelligence Brief

NephroNet, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Acthar Gel 80 UNT/ML Injectable Solution Acthar Gel 80 UNT/ML Injectable Solution marketed Adrenocorticotropic hormone (ACTH) analog Melanocortin-2 receptor (MC2R) Immunology / Rheumatology / Nephrology
Oral Tab Tacrolimus Oral Tab Tacrolimus marketed Calcineurin inhibitor Calcineurin (via FKBP12 binding) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Albert Einstein Healthcare Network · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Andrew B Adams · 1 shared drug class
  4. Armando Torres Ramírez · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Astellas Pharma China, Inc. · 1 shared drug class
  7. Astellas Pharma Europe Ltd. · 1 shared drug class
  8. Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NephroNet, Inc.:

Cite this brief

Drug Landscape (2026). NephroNet, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nephronet-inc. Accessed 2026-05-15.

Related